30% at 1 year after HCT and 26% at 2 years. Adult patients who had steroid-refractory GVHD within 2 weeks of onset had a 1-year survival of 16% compared to 88% among steroid refractory pediatric patients. During the 14 day periods immediately before or after the onset of GI symptoms, these risk factors for overall mortality were identified by multivariable analysis.
In a subgroup of patients who underwent endoscopy (N 5 73), a finding of ulcerated mucosa was predictive of mortality (HR 2.52, p 5 0.02). Within 2 weeks of GI symptom onset, mortality in patients with GVHD can be predicted by age, jaundice, hypoalbuminemia, response to prednisone, and presence of ulcerated mucosa at endoscopy. More effective early treatment in GI GVHD patients at risk for mortality is likely to be more useful than salvage therapy for steroid-refractory patients. Redirecting specificity of human T cells to tumor antigens using chimeric antigen receptors (CARs) is a promising approach for adop-tive cell therapy. Non-viral gene transfer of a CD19-specific CAR into human peripheral blood mononuclear cell (PBMC)-derived T cells using the Sleeping Beauty system is undergoing evaluation in the autologous setting. We now are developing allogeneic CAR 1 T cells for infusion after hematopoietic stem-cell transplantation (HSCT) to improve the graft-versus-leukemia (GvL) effect. However, CAR 1 T cells possess endogenous T-cell receptors (TCR) retaining broad TCR Vb subfamily distribution, and may therefore mediate alloresponses to histocompatibility antigens. Alloanergization of donor-derived T cells (induction of alloantigen-specific hyporesponsiveness by allostimulation with blockade of CD28-mediated costimulation) is a simple and clinically-proven approach to selectively abrogate alloresponses. We therefore assessed whether alloanergization could reduce alloresponses in CAR 1 T cells without loss of CD19-specific redirected killing. Alloproliferative responses were detected in CAR 1 T cells generated from healthy donors when co-cultured with HLA-mismatched irradiated stimulator PBMC. To reduce potential for GvHD, CAR 1 T cells were alloanergized by co-culture with stimulator PBMC and clinical-grade humanized monoclonal anti-B7.1 and -B7.2 antibodies, resulting in a median 75% reduction in subsequent stimulator-specific alloresponses without loss of proliferation to mitogenic CD3. Alloanergization was further improved (median 93% reduction in alloresponses) with use of CD19-depleted stimulator PBMC to remove non-allospecific B cell-mediated stimulation of CAR 1 T cells. Importantly alloanergized CAR 1 T cells retained CD19-specific CAR expression and CD19-specific killing. In aggregate, as allogeneic CAR 1 T cells exhibit alloproliferative responses in vitro they have potential to cause GvHD. To overcome this potential problem, we have demonstrated that deleterious alloresponses can be abrogated by the clinically-applicable technique of alloanergization without loss of proliferation to mitogenic stimulus, expression of CAR, or specific killing of CD19 1 targets. Thus, two techniques, CAR insertion and alloanergization, that have both achieved regulatory approval can be employed together to produce non-alloreactive donor T cells for clinical use to augment GvL after allogeneic HSCT for B-cell malignancies. Contribution of different T cell subsets in the development of graft-versus-host disease (GVHD) is an active area of research. T helper type-1 (Th1) cells were believed to be the most important CD4 T cell subset to induce GVHD through inflammatory cytokines including IFNg and TNFa. However, the concept was seriously challenged by recent findings that T cells deficient for IFNg, Stat4 or T-bet caused exacerbated GVHD. These results indicate that Th1 subset is not required for the induction of GVHD and other Th subsets are sufficient. Th17 is a newly identified T cell lineage that secretes IL-17A among other pro-inflammatory cytokines. Th17 cells play a critical role in autoimmune diseases, including causing a systemic autoimmune disorder resembling GVHD. However, the role of Th17 cells in the pathogenesis of classical GVHD remains unclear. In the current study, by transferring in vitro generated Th17 cells together with donor bone marrow into lethally irradiated allogeneic recipients, we demonstrated that allogeneic Th17 cells were highly pathogenic to induce GVHD, more so than naïve or Th1 controls. The same Th17 cells, however, caused no pathology in the syngeneic recipients, indicating antigen-activation was required for these cells to induce GVHD. High potency of Th17 cells in the induction of GVHD was correlated with their superior ability to expand and to infiltrate in GVHD target organs. After transfer into recipients, Th17 cells produced significant levels of IFNg and TNFa besides IL-17A. Furthermore, IFNg KO Th17 cells had reduced ability to cause GVHD compared to wild type (WT) Th17 cells, indicating that IFNg also contributes to the pathogenicity of Th17 cells. Our findings show that both Th1 and Th17 cells participate in the pathogenesis of acute GVHD.
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